Stockscreener 앱 받기
2.35
0.84%
-0.02
시간 외 거래:
2.35
전일 마감가:
$2.37
열려 있는:
$2.32
하루 거래량:
2,530
Relative Volume:
0.01
시가총액:
$123.05M
수익:
$18.85M
순이익/손실:
$-119.67M
주가수익비율:
-1.1566
EPS:
-2.0318
순현금흐름:
$-89.09M
1주 성능:
-4.08%
1개월 성능:
-14.23%
6개월 성능:
-19.24%
1년 성능:
-44.05%
1일 변동 폭
$2.2856
$2.35
1주일 범위
$2.22
$2.45
52주 변동 폭
$1.53
$4.75
인벤티바 Stock (IVA) Company Profile
IVA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IVA
Inventiva Adr
|
2.35 | 123.05M | 18.85M | -119.67M | -89.09M | -2.6346 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
인벤티바 Stock (IVA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-11-12 | 개시 | UBS | Neutral |
| 2023-10-27 | 개시 | Canaccord Genuity | Buy |
| 2023-05-31 | 개시 | ROTH MKM | Buy |
| 2023-05-19 | 업그레이드 | Societe Generale | Sell → Buy |
| 2023-03-17 | 개시 | Stifel | Buy |
| 2022-11-15 | 다운그레이드 | Societe Generale | Buy → Sell |
| 2021-03-08 | 다운그레이드 | Societe Generale | Buy → Sell |
| 2020-08-05 | 개시 | ROTH Capital | Buy |
| 2020-08-04 | 개시 | Guggenheim | Buy |
| 2020-08-04 | 개시 | Stifel | Buy |
모두보기
인벤티바 주식(IVA)의 최신 뉴스
Inventiva reports 2024 Third Quarter Financial Information¹ - GlobeNewswire Inc.
Inventiva (IVA) Loses -17.66% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - MSN
Inventiva ADR (IVA) Stock: A Year of Stock Market Ups and Downs - The InvestChronicle
Stifel reiterates Buy rating on Inventiva stock, cites financing deal - Investing.com
Why Are Criminals Still in Power? 151 Lawmakers with Charges of Crimes Against Women Continue to Hold Office! Is This the End of Integrity in Indian Politics? - Inventiva
Why Paramount Global Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving PremarketParamount ... - Benzinga
Inventiva provides an update on its NATiV3 clinical program evaluating lanifibranor in patients with MASH/NASH and ... - GlobeNewswire Inc.
Down -27.95% in 4 Weeks, Here's Why You Should You Buy the Dip in Inventiva (IVA) - Yahoo Finance
Will Election Commission Make Sure That Elections In 2024 Will Be Completely Fair? - Inventiva
Inventiva’s LEGEND Trial Shows Promising Results - TipRanks
Is SBI's Demand For Extra Time To Disclose Details Of Electoral Bonds 1 Attempt To Hide The Doings And Doers Of ‘Great Political Chanda’? - Inventiva
Supreme Court To Hear Plea Against Electoral Bonds From October 31 - Inventiva
National Parties Declare Assets Worth Rs 8,829 Crore In 2021-22: Report - Inventiva
Explosive Showdown: Rahul Yadav-Led 4B Networks Clash with Info Edge in High-Stakes Arbitration Battle - Inventiva
The Indian Chief Ministers Are A Bunch Of Crorepatis While The Average Middle-Class Indian Tax Payer Is Struggling To Survive - Inventiva
Top 10 Best Handicraft Companies In USA 2023 - Inventiva
Top 20 Best Hardware & Networking Company In India 2023 - Inventiva
Top 10 Best Law Firms In India 2023. - Inventiva
Top 10 Best LegalTech companies in India 2023 - Inventiva
An Interesting Telecom Startup Announced Funding Of INR 30 Crore - Inventiva
TCS, Infosys, Wipro Hire Over 1 Lakh Employees This Fiscal. Know Details - Inventiva
8 US equities have commenced trading on the NSE IFSC in GIFT City; All information about how to start trading through IFSC and should you put money in US stocks? - Inventiva
Innovation And Technology Revolutionizing The Legal Landscape In India 2022 - Inventiva
India Has Its First Most Awaited International Arbitration Centre In Hyderabad In 2021. - Inventiva
The Daily Biotech Pulse: Fluidigm's Saliva-Based COVID Test Approved In Europe, China Backs Amarin's Vascepa - Yahoo Finance
The Daily Biotech Pulse: FDA Greenlights Merck's Heart Failure Drug, Histogen Hit With Clinical Hold, Aptorum Gets Nod For Commencing Human Study - Markets Insider
The Daily Biotech Pulse: Moderna To Kickstart Phase 3 Study On July 27, Immutep Awarded Antibody Patent - Yahoo Finance
인벤티바 (IVA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.88%
2.65%
자본화:
|
볼륨(24시간):